Pioglitazone: Indian perspective.
Pioglitazone was approved in 1999 as an adjunct to exercise and diet to improve glycemic control in adults with type 2 diabetes mellitus, primarily by reducing insulin resistance. Beyond these effects on glucose metabolism, pioglitazone has positive effects on lipid metabolism, blood pressure, endothelial function, adiponectin, and C-reactive protein levels. These make pioglitazone treatment effective beyond glucose control. Pioglitazone generally has been viewed as a safer option for patients who warrant treatment with a thiazolidinedione-class drug. There has been some recent data on cancer incidence in patients on pioglitazone, which is currently being reviewed by drug regulatory authorities in the United States and in Europe. Given the benefits of pioglitazone, alone and in combination, it would be appropriate to continue judicious use of the drug in patients who may benefit from its use.
Department of Endocrinology, Regency Hospital, Kanpur, India.
Rishi
R
Shukla
Sanjay
S
Kalra